Alkermes plc. vs Sarepta Therapeutics
Sarepta Therapeutics is the larger business, with $2.20bn of revenue in fiscal 2025 against $1.48bn for Alkermes plc. (1.5 times as much). Sarepta Therapeutics grew faster (15.6% against -5.2%). Alkermes plc. kept more of each dollar of sales as profit: a net margin of 16.4% against -32.5%. Alkermes plc. carries less debt relative to equity (0.0% against 72.7%).
| Latest fiscal year | Alkermes plc.ALKS, 2025 | Sarepta TherapeuticsSRPT, 2025 |
|---|---|---|
| Revenue | $1.48bn | $2.20bn |
| Revenue growth | -5.2% | 15.6% |
| Net income | $242m | −$713m |
| Operating margin | 17.2% | -31.8% |
| Net margin | 16.4% | -32.5% |
| Return on equity | 14.7% | -53.5% |
| Free cash flow | $480m | −$307m |
| Cash | $389m | $801m |
| Total debt | $0 | $829m |
| Debt to equity | 0.0% | 72.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $25.0m |
| Employees | 2,050 | 835 |
| Market value | $7.84bn | $1.96bn |
| Price vs our value range | Within our value range | — |
| Moat score | 63 (Moderate) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 2 sales |